{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:22:28Z","timestamp":1794856948555,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20356, 31730057, and 91540205"],"award-info":[{"award-number":["U21A20356, 31730057, and 91540205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LD21C070001"],"award-info":[{"award-number":["LD21C070001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Loss of TGF-\u03b2-mediated growth suppression is a major contributor to the development of cancers, best exemplified by loss-of-function mutations in genes encoding components of the TGF-\u03b2 signaling pathway in colorectal and pancreatic cancers. Alternatively, gain-of-function oncogene mutations can also disrupt antiproliferative TGF-\u03b2 signaling. However, the molecular mechanisms underlying oncogene-induced modulation of TGF-\u03b2 signaling have not been extensively investigated. Here, we show that the oncogenic BCR-ABL1 of chronic myelogenous leukemia (CML) and the cellular ABL1 tyrosine kinases phosphorylate and inactivate Smad4 to block antiproliferative TGF-\u03b2 signaling. Mechanistically, phosphorylation of Smad4 at Tyr195, Tyr301, and Tyr322 in the linker region interferes with its binding to the transcription co-activator p300\/CBP, thereby blocking the ability of Smad4 to activate the expression of cyclin-dependent kinase (CDK) inhibitors and induce cell cycle arrest. In contrast, the inhibition of BCR-ABL1 kinase with Imatinib prevented Smad4 tyrosine phosphorylation and re-sensitized CML cells to TGF-\u03b2-induced antiproliferative and pro-apoptotic responses. Furthermore, expression of phosphorylation-site-mutated Y195F\/Y301F\/Y322F mutant of Smad4 in <jats:italic>Smad4<\/jats:italic>-null CML cells enhanced antiproliferative responses to TGF-\u03b2, whereas the phosphorylation-mimicking Y195E\/Y301E\/Y322E mutant interfered with TGF-\u03b2 signaling and enhanced the in vivo growth of CML cells. These findings demonstrate the direct role of BCR-ABL1 tyrosine kinase in suppressing TGF-\u03b2 signaling in CML and explain how Imatinib-targeted therapy restored beneficial TGF-\u03b2 anti-growth responses.<\/jats:p>","DOI":"10.1038\/s41392-023-01327-5","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T01:02:17Z","timestamp":1679619737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-\u03b2 growth-suppressive signaling in BCR-ABL1-positive leukemia"],"prefix":"10.1038","volume":"8","author":[{"given":"Lijing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenfang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1690-646X","authenticated-orcid":false,"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-5443","authenticated-orcid":false,"given":"Pinglong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-3353","authenticated-orcid":false,"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5603-4160","authenticated-orcid":false,"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Hua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"1327_CR1","doi-asserted-by":"publisher","first-page":"eaav5183","DOI":"10.1126\/scisignal.aav5183","volume":"12","author":"R Derynck","year":"2019","unstructured":"Derynck, R. & Budi, E. H. Specificity, versatility, and control of TGF-\u03b2 family signaling. Sci. Signal. 12, eaav5183 (2019).","journal-title":"Sci. Signal."},{"key":"1327_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ceb.2019.07.007","volume":"61","author":"Y Yu","year":"2019","unstructured":"Yu, Y. & Feng, X.-H. TGF-\u03b2 signaling in cell fate control and cancer. Curr. Opin. Cell Biol. 61, 56\u201363 (2019).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1327_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck, R., Turley, S. J. & Akhurst, R. J. TGF\u03b2 biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9\u201334 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1327_CR4","doi-asserted-by":"publisher","first-page":"a022087","DOI":"10.1101\/cshperspect.a022087","volume":"8","author":"P Xu","year":"2016","unstructured":"Xu, P., Lin, X. & Feng, X.-H. Posttranslational regulation of Smads. Cold Spring Harb. Perspect. Biol. 8, a022087 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1327_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev.cellbio.21.022404.142018","volume":"21","author":"X-H Feng","year":"2005","unstructured":"Feng, X.-H. & Derynck, R. Specificity and versatility in TGF-\u03b2 signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659\u2013693 (2005).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"1327_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0092-8674(02)00690-6","volume":"109","author":"QL Li","year":"2002","unstructured":"Li, Q. L. et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109, 113\u2013124 (2002).","journal-title":"Cell"},{"key":"1327_CR7","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1096\/fj.14-249532","volume":"28","author":"J Fortin","year":"2014","unstructured":"Fortin, J., Boehm, U., Deng, C.-X., Treier, M. & Bernard, D. J. Follicle-stimulating hormone synthesis and fertility depend on Smad4 and FOXL2. FASEB J. 28, 3396\u20133410 (2014).","journal-title":"FASEB J."},{"key":"1327_CR8","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1101\/gad.12.14.2153","volume":"12","author":"XH Feng","year":"1998","unstructured":"Feng, X. H., Zhang, Y., Wu, R. Y. & Derynck, R. The tumor suppressor Smad4\/DPC4 and transcriptional adaptor CBP\/p300 are coactivators for smad3 in TGF-\u03b2-induced transcriptional activation. Genes Dev. 12, 2153\u20132163 (1998).","journal-title":"Genes Dev."},{"key":"1327_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/onc.2016.204","volume":"36","author":"T Liu","year":"2017","unstructured":"Liu, T. et al. Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-\u03b2 responses. Oncogene 36, 362\u2013372 (2017).","journal-title":"Oncogene"},{"key":"1327_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nature01119","volume":"419","author":"J Seoane","year":"2002","unstructured":"Seoane, J., Le, H.-V. & Massagu\u00e9, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729\u2013734 (2002).","journal-title":"Nature"},{"key":"1327_CR11","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1093\/emboj\/19.19.5178","volume":"19","author":"XH Feng","year":"2000","unstructured":"Feng, X. H., Lin, X. & Derynck, R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J. 19, 5178\u20135193 (2000).","journal-title":"EMBO J."},{"key":"1327_CR12","doi-asserted-by":"publisher","first-page":"10700","DOI":"10.1074\/jbc.M007499200","volume":"276","author":"S Nishimori","year":"2001","unstructured":"Nishimori, S. et al. Smad-mediated transcription is required for transforming growth factor-beta 1-induced p57(Kip2) proteolysis in osteoblastic cells. J. Biol. Chem. 276, 10700\u201310705 (2001).","journal-title":"J. Biol. Chem."},{"key":"1327_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.devcel.2009.01.022","volume":"16","author":"F Dai","year":"2009","unstructured":"Dai, F., Lin, X., Chang, C. & Feng, X.-H. Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-\u03b2 signaling. Dev. Cell 16, 345\u2013357 (2009).","journal-title":"Dev. Cell"},{"key":"1327_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.cell.2006.03.044","volume":"125","author":"X Lin","year":"2006","unstructured":"Lin, X. et al. PPM1A functions a Smad phosphatase to terminate TGF-\u03b2 signaling. Cell 125, 915\u2013928 (2006).","journal-title":"Cell"},{"key":"1327_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-pathol-011110-130235","volume":"6","author":"ER Fearon","year":"2011","unstructured":"Fearon, E. R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. Mech. Dis. 6, 479\u2013507 (2011).","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"1327_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/abbs\/gmy092","volume":"50","author":"S Gu","year":"2018","unstructured":"Gu, S. & Feng, X.-H. TGF-\u03b2 signaling in cancer. Acta Biochim. Biophys. Sin. 50, 941\u2013949 (2018).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"1327_CR17","doi-asserted-by":"publisher","first-page":"a027987","DOI":"10.1101\/cshperspect.a027987","volume":"9","author":"K Naka","year":"2017","unstructured":"Naka, K. & Hirao, A. Regulation of hematopoiesis and hematological disease by TGF-\u03b2 Family signaling molecules. Cold Spring Harb. Perspect. Biol. 9, a027987 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1327_CR18","doi-asserted-by":"publisher","first-page":"40282","DOI":"10.1074\/jbc.C000485200","volume":"275","author":"A Jakubowiak","year":"2000","unstructured":"Jakubowiak, A. et al. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1\/ETO leukemia-associated fusion protein. J. Biol. Chem. 275, 40282\u201340287 (2000).","journal-title":"J. Biol. Chem."},{"key":"1327_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/27945","volume":"394","author":"M Kurokawa","year":"1998","unstructured":"Kurokawa, M. et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 394, 92\u201396 (1998).","journal-title":"Nature"},{"key":"1327_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3563","volume":"13","author":"EK Greuber","year":"2013","unstructured":"Greuber, E. K., Smith-Pearson, P., Wang, J. & Pendergast, A. M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer 13, 559\u2013571 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"1327_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","volume":"22","author":"S Wong","year":"2004","unstructured":"Wong, S. & Witte, O. N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22, 247\u2013306 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"1327_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493\u2013502 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1327_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","volume":"25","author":"S Roychowdhury","year":"2011","unstructured":"Roychowdhury, S. & Talpaz, M. Managing resistance in chronic myeloid leukemia. Blood Rev. 25, 279\u2013290 (2011).","journal-title":"Blood Rev."},{"key":"1327_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1097-2765(00)80061-1","volume":"1","author":"L Zawel","year":"1998","unstructured":"Zawel, L. et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1, 611\u2013617 (1998).","journal-title":"Mol. Cell"},{"key":"1327_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O\u2019Hare","year":"2012","unstructured":"O\u2019Hare, T., Zabriskie, M. S., Eiring, A. M. & Deininger, M. W. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat. Rev. Cancer 12, 513\u2013526 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1327_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561\u2013566 (1996).","journal-title":"Nat. Med."},{"key":"1327_CR27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.191.6.977","volume":"191","author":"M Horita","year":"2000","unstructured":"Horita, M. et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med. 191, 977\u2013984 (2000).","journal-title":"J. Exp. Med."},{"key":"1327_CR28","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1038\/sj.leu.2404792","volume":"21","author":"S Corm","year":"2007","unstructured":"Corm, S. et al. Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR\/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. Leukemia 21, 2376\u20132377 (2007).","journal-title":"Leukemia"},{"key":"1327_CR29","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1074\/jbc.275.3.2115","volume":"275","author":"MP de Caestecker","year":"2000","unstructured":"de Caestecker, M. P. et al. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. J. Biol. Chem. 275, 2115\u20132122 (2000).","journal-title":"J. Biol. Chem."},{"key":"1327_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/374081a0","volume":"374","author":"Z Arany","year":"1995","unstructured":"Arany, Z., Newsome, D., Oldread, E., Livingston, D. M. & Eckner, R. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 374, 81\u201384 (1995).","journal-title":"Nature"},{"key":"1327_CR31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides, T. Chromatin modifications and their function. Cell 128, 693\u2013705 (2007).","journal-title":"Cell"},{"key":"1327_CR32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1126\/science.271.5247.350","volume":"271","author":"SA Hahn","year":"1996","unstructured":"Hahn, S. A. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350\u2013353 (1996).","journal-title":"Science"},{"key":"1327_CR33","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1073\/pnas.92.12.5501","volume":"92","author":"RJ Capocasale","year":"1995","unstructured":"Capocasale, R. J. et al. Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from S\u00e9zary patients. Proc. Natl Acad. Sci. USA 92, 5501\u20135505 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1327_CR34","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031197","volume":"351","author":"LA Wolfraim","year":"2004","unstructured":"Wolfraim, L. A. et al. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N. Engl. J. Med. 351, 552\u2013559 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1327_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cancergencyto.2010.03.004","volume":"200","author":"E De Braekeleer","year":"2010","unstructured":"De Braekeleer, E. et al. Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008. Cancer Genet. Cytogenet. 200, 8\u201315 (2010).","journal-title":"Cancer Genet. Cytogenet."},{"key":"1327_CR36","doi-asserted-by":"publisher","first-page":"114155","DOI":"10.1016\/j.bcp.2020.114155","volume":"180","author":"X Li","year":"2020","unstructured":"Li, X. & Feng, X.-H. SMAD-oncoprotein interplay: Potential determining factors in targeted therapies. Biochem. Pharmacol. 180, 114155 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"1327_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1097-2765(01)00430-0","volume":"9","author":"X-H Feng","year":"2002","unstructured":"Feng, X.-H., Liang, Y.-Y., Liang, M., Zhai, W. & Lin, X. Direct Interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-\u03b2-mediated induction of the CDK inhibitor p15(Ink4B). Mol. Cell 9, 133\u2013143 (2002).","journal-title":"Mol. Cell"},{"key":"1327_CR38","doi-asserted-by":"publisher","first-page":"e99945","DOI":"10.15252\/embj.201899945","volume":"38","author":"B Yuan","year":"2019","unstructured":"Yuan, B. et al. PTPN3 acts as a tumor suppressor and boosts TGF-\u03b2 signaling independent of its phosphatase activity. EMBO J. 38, e99945 (2019).","journal-title":"EMBO J."},{"key":"1327_CR39","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/0008-5472.CAN-07-0008","volume":"68","author":"D Wang","year":"2008","unstructured":"Wang, D. et al. BCL6 represses Smad signaling in transforming growth factor-beta resistance. Cancer Res. 68, 783\u2013789 (2008).","journal-title":"Cancer Res."},{"key":"1327_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1126\/science.286.5440.771","volume":"286","author":"SL Stroschein","year":"1999","unstructured":"Stroschein, S. L., Wang, W., Zhou, S., Zhou, Q. & Luo, K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein. Science 286, 771\u2013774 (1999).","journal-title":"Science"},{"key":"1327_CR41","doi-asserted-by":"publisher","first-page":"35269","DOI":"10.1074\/jbc.274.49.35269","volume":"274","author":"S Akiyoshi","year":"1999","unstructured":"Akiyoshi, S. et al. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J. Biol. Chem. 274, 35269\u201335277 (1999).","journal-title":"J. Biol. Chem."},{"key":"1327_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41556-018-0264-3","volume":"21","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. ALK phosphorylates Smad4 on tyrosine to disable TGF-\u03b2 tumour suppressor functions. Nat. Cell Biol. 21, 179\u2013189 (2019).","journal-title":"Nat. Cell Biol."},{"key":"1327_CR43","first-page":"51","volume":"3","author":"R Ferdinand","year":"2012","unstructured":"Ferdinand, R., Mitchell, S., Batson, S. & Tumur, I. Treatments for chronic myeloid leukemia: a qualitative systematic review. J. Blood Med. 3, 51\u201376 (2012).","journal-title":"J. Blood Med."},{"key":"1327_CR44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1327_CR45","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1158\/0008-5472.CAN-16-0842","volume":"77","author":"X Zheng","year":"2017","unstructured":"Zheng, X. et al. EpCAM inhibition sensitizes chemoresistant leukemia to immune surveillance. Cancer Res. 77, 482\u2013493 (2017).","journal-title":"Cancer Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01327-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01327-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01327-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T01:02:22Z","timestamp":1679619742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01327-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01327-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"assertion":[{"value":"24 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}